Back to Journals » International Journal of General Medicine » Volume 14

Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate

Authors Liang Y, Chen M, Tan C, Tu C, Zheng X, Liu J

Received 11 November 2020

Accepted for publication 8 January 2021

Published 4 February 2021 Volume 2021:14 Pages 357—359

DOI https://doi.org/10.2147/IJGM.S291695

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser


Yingjian Liang,* Meizhu Chen,* Cuiyan Tan, Changli Tu, Xiaobin Zheng, Jing Liu

Department of Pulmonary and Critical Care Medicine (PCCM), The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Jing Liu; Xiaobin Zheng
The Fifth Affiliated Hospital of Sun Yat-Sen University, 52 East Meihua Road, Zhuhai City, 519000, People’s Republic of China
Tel/Fax +86(0)7562528733
Email liujing25@mail.sysu.edu.cn; zhxbin@mail.sysu.edu.cn

Abstract: Awareness of the management of coronavirus disease 2019 (COVID-19) and airway diseases can effectively help clinical physician during the coronavirus pandemic. Herein, we elucidated a COVID-19 case coexisting with severe asthma. Budesonide/glycopyrrolate/formoterol fumarate (BGF) was used as sequential medicine to systemic glucocorticoids for his persisted symptoms related to bronchospasms. Our case suggests patients with long-term airway diseases like asthma probably attribute their symptoms to COVID-19 instead of primary diseases, which make it more difficult in the symptom control. BGF is able to be an effective and convenient choice as sequential medicine to systemic glucocorticoids in some refractory asthmatic patients complicated with COVID-19.

Keywords: coronavirus disease 2019, asthma, budesonide/glycopyrrolate/formoterol fumarate, sequential treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]